{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-13T01:23:00.602990+00:00","company":{"ticker":"ROIV","cik":1635088,"company_name":"Roivant Sciences Ltd."},"pagination":{"limit":100,"returned":33,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"Moderna, Inc. and ModernaTx, Inc.","detail":"settlement","count":2,"first_seen":"2026-03-03T23:59:59+00:00","last_seen":"2026-03-23T23:59:59+00:00","evidence_fact_ids":[27710,30273]},{"display_name":"Cantor Fitzgerald & Co.","detail":"underwriting","count":1,"first_seen":"2022-11-10T23:59:59+00:00","last_seen":"2022-11-10T23:59:59+00:00","evidence_fact_ids":[197373]},{"display_name":"Goldman Sachs & Co. LLC, SVB Securities LLC, Cowen and Company, LLC and Cantor Fitzgerald & Co.","detail":"underwriting","count":1,"first_seen":"2023-02-07T23:59:59+00:00","last_seen":"2023-02-07T23:59:59+00:00","evidence_fact_ids":[181255]},{"display_name":"Roche Holdings, Inc.","detail":"asset_purchase","count":1,"first_seen":"2023-10-23T23:59:59+00:00","last_seen":"2023-10-23T23:59:59+00:00","evidence_fact_ids":[105124]}],"ma_counterparty":[{"display_name":"Roche Holdings, Inc.","detail":"disposition","count":1,"first_seen":"2023-12-14T23:59:59+00:00","last_seen":"2023-12-14T23:59:59+00:00","evidence_fact_ids":[88393]}]},"facts":[{"fact_type":"earnings_release","fact_key":"45519c433c69e815f019eb6ceb6628b043ebf514","cik":1635088,"ticker":"ROIV","company_name":"Roivant Sciences Ltd.","filed_at":"2026-05-20T11:14:10+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"fourth quarter and fiscal year ended March 31, 2026","report_date":"2026-05-20","result_type":"reported_results","revenue_text":null},"claim":"Roivant Sciences Ltd. reported financial results for fourth quarter and fiscal year ended March 31, 2026.","evidence_excerpt":"On May 20, 2026, Roivant Sciences Ltd. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended March 31, 2026.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001635088-26-000060","anchor_url":"https://secwatch.observer/filing/0001635088-26-000060#claim-45519c433c69e815f019eb6ceb6628b043ebf514","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1635088/000163508826000060/0001635088-26-000060-index.htm"},{"fact_type":"material_agreement","fact_key":"40d7e8acc138e510c070e5758de838bfde1a59d3","cik":1635088,"ticker":"ROIV","company_name":"Roivant Sciences Ltd.","filed_at":"2026-03-23T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Settlement Agreement","agreement_type":"settlement","counterparty":"Moderna, Inc. and ModernaTx, Inc. (together, \"Moderna\")","effective_date":"2026-03-03","item_codes_triggered":["1.01"],"value_text":null},"claim":"Roivant Sciences Ltd. entered into Settlement Agreement with Moderna, Inc. and ModernaTx, Inc. (together, \"Moderna\") (effective 2026-03-03).","evidence_excerpt":"on March 3, 2026, Genevant, Arbutus and, solely for certain purposes, GSL, entered into a Settlement Agreement with Moderna to resolve all patent infringement litigation between Genevant/Arbutus and Moderna pending in the U.S. and internationally relating to Moderna's use of Genevant/Arbutus’ lipid nanoparticle delivery technology in its vaccines.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-26-010656","anchor_url":"https://secwatch.observer/filing/0001140361-26-010656#claim-40d7e8acc138e510c070e5758de838bfde1a59d3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036126010656/0001140361-26-010656-index.htm"},{"fact_type":"material_agreement","fact_key":"45627f24230e0c946323db9cced6e1d3a2d9fede","cik":1635088,"ticker":"ROIV","company_name":"Roivant Sciences Ltd.","filed_at":"2026-03-03T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Settlement Agreement","agreement_type":"settlement","counterparty":"Moderna, Inc. and ModernaTx, Inc.","effective_date":"2026-03-03","item_codes_triggered":["1.01"],"value_text":"$950.0 million noncontingent lump sum payment"},"claim":"Roivant Sciences Ltd. entered into Settlement Agreement with Moderna, Inc. and ModernaTx, Inc. valued at $950.0 million noncontingent lump sum payment (effective 2026-03-03).","evidence_excerpt":"On March 3, 2026 (the “Effective Date”), Genevant Sciences GmbH (“Genevant”), a subsidiary of Roivant Sciences Ltd. (the “Company” or “Roivant”), Arbutus Biopharma Corp. (together with Genevant, “Genevant/Arbutus”), and, solely for certain purposes, Genevant Sciences Ltd., and Moderna, Inc. and ModernaTx, Inc. (together, “Moderna”) entered into a settlement agreement (the “Settlement Agreement”)","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-26-007548","anchor_url":"https://secwatch.observer/filing/0001140361-26-007548#claim-45627f24230e0c946323db9cced6e1d3a2d9fede","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036126007548/0001140361-26-007548-index.htm"},{"fact_type":"executive_change","fact_key":"2311003321","cik":1635088,"ticker":"ROIV","company_name":"Roivant Sciences Ltd.","filed_at":"2025-03-20T23:59:59+00:00","payload":{"action":"stepped down","action_category":"departure","departure_tone":"routine","effective_date":"2025-02-20","interim":false,"role":"Chief Accounting Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Rakhi Kumar departed as Chief Accounting Officer at Roivant Sciences Ltd..","evidence_excerpt":"Ms. Kumar stepped down from her role effective February 20, 2025.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-25-009696","anchor_url":"https://secwatch.observer/filing/0001140361-25-009696#claim-2311003321","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125009696/0001140361-25-009696-index.htm"},{"fact_type":"executive_change","fact_key":"245096a0ec","cik":1635088,"ticker":"ROIV","company_name":"Roivant Sciences Ltd.","filed_at":"2025-02-21T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-02-20","interim":false,"role":"Principal Accounting Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Jennifer Humes was appointed as Principal Accounting Officer at Roivant Sciences Ltd..","evidence_excerpt":"The Company has appointed Jennifer Humes to serve as its Principal Accounting Officer and as Chief Accounting Officer of RSI from the Effective Date.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-25-005445","anchor_url":"https://secwatch.observer/filing/0001140361-25-005445#claim-245096a0ec","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125005445/0001140361-25-005445-index.htm"},{"fact_type":"executive_change","fact_key":"537ab25999","cik":1635088,"ticker":"ROIV","company_name":"Roivant Sciences Ltd.","filed_at":"2025-02-21T23:59:59+00:00","payload":{"action":"stepped down","action_category":"departure","departure_tone":"routine","effective_date":"2025-02-20","interim":false,"role":"Principal Accounting Officer","role_category":"other_named_officer","successor_name":"Jennifer Humes","successor_named":true},"claim":"Rakhi Kumar departed as Principal Accounting Officer at Roivant Sciences Ltd..","evidence_excerpt":"Rakhi Kumar stepped down from her role as the Principal Accounting Officer of Roivant Sciences Ltd. (the “Company”) and Chief Accounting Officer of the Company’s subsidiary, Roivant Sciences, Inc. (“RSI”) effective February 20, 2025 (the “Effective Date”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-25-005445","anchor_url":"https://secwatch.observer/filing/0001140361-25-005445#claim-537ab25999","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125005445/0001140361-25-005445-index.htm"},{"fact_type":"earnings_release","fact_key":"4c6fd4a726f6f21c491f1355bd5c777dd4583b80","cik":1635088,"ticker":"ROIV","company_name":"Roivant Sciences Ltd.","filed_at":"2024-02-13T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the third quarter ended December 31, 2023","report_date":"2024-02-13","result_type":"reported_results","revenue_text":null},"claim":"Roivant Sciences Ltd. reported financial results for the third quarter ended December 31, 2023.","evidence_excerpt":"Roivant Sciences Ltd. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended December 31, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-24-007259","anchor_url":"https://secwatch.observer/filing/0001140361-24-007259#claim-4c6fd4a726f6f21c491f1355bd5c777dd4583b80","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124007259/0001140361-24-007259-index.htm"},{"fact_type":"ma_transaction","fact_key":"26ef81efb37a3e19760432b9a0c0613cdbb69fae","cik":1635088,"ticker":"ROIV","company_name":"Roivant Sciences Ltd.","filed_at":"2023-12-14T23:59:59+00:00","payload":{"action":"disposition","closing_date":"2023-12-14","consideration_text":"approximately $7.1 billion in cash","counterparty":"Roche Holdings, Inc.","effective_date":"2023-12-14","item_codes_triggered":["2.01"]},"claim":"Roivant Sciences Ltd. completed a disposition involving Roche Holdings, Inc. for approximately $7.1 billion in cash (closed 2023-12-14).","evidence_excerpt":"On December 14, 2023, pursuant to the Purchase Agreement, the Buyer completed the Transaction for total consideration of approximately $7.1 billion in cash at the closing of the Transaction (the “Closing”), paid or to be paid to all of Telavant’s equity holders, including holders of restricted stock units, on a pro rata basis relative to their ownership of Telavant prior to the Closing.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-23-057578","anchor_url":"https://secwatch.observer/filing/0001140361-23-057578#claim-26ef81efb37a3e19760432b9a0c0613cdbb69fae","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123057578/0001140361-23-057578-index.htm"},{"fact_type":"earnings_release","fact_key":"4c328591d3d5feaff5cbae1acf517b38eafede4b","cik":1635088,"ticker":"ROIV","company_name":"Roivant Sciences Ltd.","filed_at":"2023-11-13T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the second quarter ended September 30, 2023","report_date":"2023-11-13","result_type":"reported_results","revenue_text":null},"claim":"Roivant Sciences Ltd. reported financial results for the second quarter ended September 30, 2023.","evidence_excerpt":"On November 13, 2023, Roivant Sciences Ltd. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-23-052718","anchor_url":"https://secwatch.observer/filing/0001140361-23-052718#claim-4c328591d3d5feaff5cbae1acf517b38eafede4b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123052718/0001140361-23-052718-index.htm"},{"fact_type":"material_agreement","fact_key":"6bcea22fa7398bb6ab204c3b9df5171d5b383a13","cik":1635088,"ticker":"ROIV","company_name":"Roivant Sciences Ltd.","filed_at":"2023-10-23T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Stock Purchase Agreement","agreement_type":"asset_purchase","counterparty":"Roche Holdings, Inc.","effective_date":"2023-10-22","item_codes_triggered":["1.01"],"value_text":"$7.1 billion in cash at the closing"},"claim":"Roivant Sciences Ltd. entered into Stock Purchase Agreement with Roche Holdings, Inc. valued at $7.1 billion in cash at the closing (effective 2023-10-22).","evidence_excerpt":"On October 22, 2023, Roivant Sciences Ltd. (the “Company”), the Company’s subsidiary Telavant Holdings, Inc. (“Telavant”), Pfizer Inc. (“Pfizer”) and Roche Holdings, Inc. (the “Buyer”) entered into a Stock Purchase Agreement (the “Purchase Agreement”), pursuant to which the Buyer agreed to acquire all of the issued and outstanding shares of capital stock of Telavant on the terms and subject to the conditions set forth in the Purchase Agreement (the “Transaction”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-23-049091","anchor_url":"https://secwatch.observer/filing/0001140361-23-049091#claim-6bcea22fa7398bb6ab204c3b9df5171d5b383a13","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123049091/0001140361-23-049091-index.htm"},{"fact_type":"material_agreement","fact_key":"e752b7cb81e363be7df02e53d26bc6bee5c9db71","cik":1635088,"ticker":"ROIV","company_name":"Roivant Sciences Ltd.","filed_at":"2023-09-29T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Purchase and Sale Agreements","agreement_type":"equity_purchase","counterparty":"certain institutional investors","effective_date":"2023-09-26","item_codes_triggered":["1.01"],"value_text":"aggregate gross proceeds of approximately $200.1 million"},"claim":"Roivant Sciences Ltd. entered into Purchase and Sale Agreements with certain institutional investors valued at aggregate gross proceeds of approximately $200.1 million (effective 2023-09-26).","evidence_excerpt":"On September 26, 2023, Roivant Sciences Ltd. (the “Company”) entered into common share purchase and sale agreements (collectively, the “Purchase and Sale Agreements”) with certain institutional investors, pursuant to which the Company agreed to issue and sell an aggregate of 19,600,685 of the Company’s common shares","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-23-046010","anchor_url":"https://secwatch.observer/filing/0001140361-23-046010#claim-e752b7cb81e363be7df02e53d26bc6bee5c9db71","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123046010/0001140361-23-046010-index.htm"},{"fact_type":"shareholder_vote","fact_key":"cf3e3427f37fb17169aaae1e31708ed6dc537c85","cik":1635088,"ticker":"ROIV","company_name":"Roivant Sciences Ltd.","filed_at":"2023-09-15T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-09-12","outcome":"passed","proposal_text":"Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm and as auditor for statutory purposes under the Bermuda Companies Act","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"253,423","votes_against":"65,948","votes_for":"709,944,901","votes_withheld":null}]},"claim":"Roivant Sciences Ltd. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm and as auditor for statutory purposes under the Bermuda Companies Act at the 2023-09-12 meeting.","evidence_excerpt":"Shareholders ratified the appointment of Ernst & Young LLP (“EY”) to serve as the Company’s independent registered public accounting firm for the fiscal year ending March 31, 2024, and to appoint EY as the Company’s auditor for statutory purposes under the Bermuda Companies Act 1981, as amended, for the fiscal year ending March 31, 2024.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001140361-23-044154","anchor_url":"https://secwatch.observer/filing/0001140361-23-044154#claim-cf3e3427f37fb17169aaae1e31708ed6dc537c85","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123044154/0001140361-23-044154-index.htm"},{"fact_type":"shareholder_vote","fact_key":"b0404db7fb8874c5401d680bdfbe0669731c9975","cik":1635088,"ticker":"ROIV","company_name":"Roivant Sciences Ltd.","filed_at":"2023-09-15T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-09-12","outcome":"passed","proposal_text":"Election of Class II Directors","proposal_type":"director_election","results":[{"broker_non_votes":"40,276,885","subject":"Daniel Gold","votes_abstain":null,"votes_against":null,"votes_for":"480,335,783","votes_withheld":"189,651,604"},{"broker_non_votes":"40,276,885","subject":"Meghan FitzGerald, DrPH","votes_abstain":null,"votes_against":null,"votes_for":"668,955,006","votes_withheld":"1,032,381"}]},"claim":"Roivant Sciences Ltd. shareholders approved Election of Class II Directors at the 2023-09-12 meeting.","evidence_excerpt":"Shareholders elected the individuals named below to serve as Class II directors of the Company, to hold office until the date of the annual general meeting of shareholders following the fiscal year ending March 31, 2026, and until their successors are duly elected and qualified, or until such director’s earlier death, resignation or removal.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001140361-23-044154","anchor_url":"https://secwatch.observer/filing/0001140361-23-044154#claim-b0404db7fb8874c5401d680bdfbe0669731c9975","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123044154/0001140361-23-044154-index.htm"},{"fact_type":"earnings_release","fact_key":"44637b9f76bb9ed64d4e775c6aeade3cb8722513","cik":1635088,"ticker":"ROIV","company_name":"Roivant Sciences Ltd.","filed_at":"2023-08-14T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fiscal quarter ended June 30, 2023","report_date":"2023-08-14","result_type":"reported_results","revenue_text":null},"claim":"Roivant Sciences Ltd. reported financial results for the fiscal quarter ended June 30, 2023.","evidence_excerpt":"On August 14, 2023, Roivant Sciences Ltd. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-23-039405","anchor_url":"https://secwatch.observer/filing/0001140361-23-039405#claim-44637b9f76bb9ed64d4e775c6aeade3cb8722513","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123039405/0001140361-23-039405-index.htm"},{"fact_type":"earnings_release","fact_key":"ee0d503dbe8198fb8c18e592c614ee29416cc475","cik":1635088,"ticker":"ROIV","company_name":"Roivant Sciences Ltd.","filed_at":"2023-08-14T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the first quarter ended June 30, 2023","report_date":"2023-08-14","result_type":"reported_results","revenue_text":"$16.7M"},"claim":"Roivant Sciences Ltd. reported the first quarter ended June 30, 2023 results: revenue $16.7M.","evidence_excerpt":"trial of IMVT-1402 remains on track for September 2023 (single-ascending dose) and October / November 2023 (multiple-ascending dose) • VTAMA® (tapinarof) net product revenue was $16.7M for the quarter ended June 30, 2023, with nearly 200,000 prescriptions written by approximately 11,500 unique prescribers since\n launch • VTAMA® gross-to-net yield was 26% for","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-23-039405","anchor_url":"https://secwatch.observer/filing/0001140361-23-039405#claim-ee0d503dbe8198fb8c18e592c614ee29416cc475","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123039405/0001140361-23-039405-index.htm"},{"fact_type":"executive_change","fact_key":"5585ff5ce2","cik":1635088,"ticker":"ROIV","company_name":"Roivant Sciences Ltd.","filed_at":"2023-08-04T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2023-08-31","interim":false,"role":"Class III Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Hiroshi Nomura resigned as Class III Director at Roivant Sciences Ltd..","evidence_excerpt":"On July 31, 2023, Hiroshi Nomura, a Class III director of Roivant Sciences Ltd. (the “Company”), informed the Company of his intention to resign from his role on the Company’s board of directors (the “Board”), effective August 31, 2023, to focus on other business affairs.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-23-038093","anchor_url":"https://secwatch.observer/filing/0001140361-23-038093#claim-5585ff5ce2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123038093/0001140361-23-038093-index.htm"},{"fact_type":"earnings_release","fact_key":"917aec2fa243dc7b8b7f26fbd75152339f6125a6","cik":1635088,"ticker":"ROIV","company_name":"Roivant Sciences Ltd.","filed_at":"2023-06-28T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth quarter and fiscal year ended March 31, 2023","report_date":"2023-06-28","result_type":"reported_results","revenue_text":null},"claim":"Roivant Sciences Ltd. reported financial results for the fourth quarter and fiscal year ended March 31, 2023.","evidence_excerpt":"On June 28, 2023, Roivant Sciences Ltd. (the “Company”) issued a press release announcing its financial results for the fiscal quarter and year ended March 31, 2023.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-23-031794","anchor_url":"https://secwatch.observer/filing/0001140361-23-031794#claim-917aec2fa243dc7b8b7f26fbd75152339f6125a6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123031794/0001140361-23-031794-index.htm"},{"fact_type":"earnings_release","fact_key":"3fee760a2e9fba8dcc614272119f4d0ead2dd46f","cik":1635088,"ticker":"ROIV","company_name":"Roivant Sciences Ltd.","filed_at":"2023-06-28T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"fourth quarter and fiscal year ended March 31, 2023","report_date":"2023-06-28","result_type":"reported_results","revenue_text":null},"claim":"Roivant Sciences Ltd. reported financial results for fourth quarter and fiscal year ended March 31, 2023.","evidence_excerpt":"Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2023, and provided an update on the business.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001140361-23-031820","anchor_url":"https://secwatch.observer/filing/0001140361-23-031820#claim-3fee760a2e9fba8dcc614272119f4d0ead2dd46f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123031820/0001140361-23-031820-index.htm"},{"fact_type":"executive_change","fact_key":"3fea7db250","cik":1635088,"ticker":"ROIV","company_name":"Roivant Sciences Ltd.","filed_at":"2023-03-16T23:59:59+00:00","payload":{"action":"appointed","action_category":"role_change","departure_tone":"not_applicable","effective_date":null,"interim":false,"role":"Chairman of the Board","role_category":"chair","successor_name":null,"successor_named":false},"claim":"Ilan Oren was appointed as Chairman of the Board at Roivant Sciences Ltd..","evidence_excerpt":"In addition, the Board has appointed Ilan Oren as Chairman of the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-23-012083","anchor_url":"https://secwatch.observer/filing/0001140361-23-012083#claim-3fea7db250","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123012083/0001140361-23-012083-index.htm"},{"fact_type":"executive_change","fact_key":"989efa66f9","cik":1635088,"ticker":"ROIV","company_name":"Roivant Sciences Ltd.","filed_at":"2023-03-16T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2023-03-13","interim":false,"role":"Class II Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Meghan M. FitzGerald was appointed as Class II Director at Roivant Sciences Ltd..","evidence_excerpt":"On March 13, 2023, the Board of Directors (the “Board”) of Roivant Sciences Ltd. (the “Company”) appointed Meghan M. FitzGerald, DrPH, to serve as a Class II director of the Company and as a member of the Nominating and Governance Committee of the Board, effective as of that date, filling a vacancy on the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-23-012083","anchor_url":"https://secwatch.observer/filing/0001140361-23-012083#claim-989efa66f9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123012083/0001140361-23-012083-index.htm"},{"fact_type":"executive_change","fact_key":"e903e34e4c","cik":1635088,"ticker":"ROIV","company_name":"Roivant Sciences Ltd.","filed_at":"2023-02-21T23:59:59+00:00","payload":{"action":"stepped down","action_category":"departure","departure_tone":"routine","effective_date":"2023-02-20","interim":false,"role":"Class II director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Vivek Ramaswamy departed as Class II director at Roivant Sciences Ltd..","evidence_excerpt":"Vivek Ramaswamy, a Class II director of Roivant Sciences Ltd. (the “Company”), stepped down from his role on the Company’s board of directors (the “Board”) effective immediately, to imminently pursue an outside opportunity.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-23-007827","anchor_url":"https://secwatch.observer/filing/0001140361-23-007827#claim-e903e34e4c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123007827/0001140361-23-007827-index.htm"},{"fact_type":"earnings_release","fact_key":"e000663eb004883200e639737614ffd5fa904b79","cik":1635088,"ticker":"ROIV","company_name":"Roivant Sciences Ltd.","filed_at":"2023-02-13T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the third quarter ended December 31, 2022","report_date":"2023-02-13","result_type":"reported_results","revenue_text":null},"claim":"Roivant Sciences Ltd. reported financial results for the third quarter ended December 31, 2022.","evidence_excerpt":"On February 13, 2023, Roivant Sciences Ltd. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended December 31, 2022.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-23-006178","anchor_url":"https://secwatch.observer/filing/0001140361-23-006178#claim-e000663eb004883200e639737614ffd5fa904b79","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123006178/0001140361-23-006178-index.htm"},{"fact_type":"material_agreement","fact_key":"7e5e5f2748083052d6881957f93e47fcd4a8518a","cik":1635088,"ticker":"ROIV","company_name":"Roivant Sciences Ltd.","filed_at":"2023-02-07T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Underwriting Agreement","agreement_type":"underwriting","counterparty":"Goldman Sachs & Co. LLC, SVB Securities LLC, Cowen and Company, LLC and Cantor Fitzgerald & Co.","effective_date":"2023-02-02","item_codes_triggered":["1.01"],"value_text":"approximately $230 million"},"claim":"Roivant Sciences Ltd. entered into Underwriting Agreement with Goldman Sachs & Co. LLC, SVB Securities LLC, Cowen and Company, LLC and Cantor Fitzgerald & Co. valued at approximately $230 million (effective 2023-02-02).","evidence_excerpt":"On February 2, 2023, Roivant Sciences Ltd. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, SVB Securities LLC, Cowen and Company, LLC and Cantor Fitzgerald & Co. (the “Representatives”), as the representatives of the underwriters named therein, relating to the issuance and sale in an underwritten offering (the “Offering”) of 30,666,665 of the Company’s common shares","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-23-005030","anchor_url":"https://secwatch.observer/filing/0001140361-23-005030#claim-7e5e5f2748083052d6881957f93e47fcd4a8518a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123005030/0001140361-23-005030-index.htm"},{"fact_type":"earnings_release","fact_key":"d852e0522b9319861d45980546afcb86d8d96b0e","cik":1635088,"ticker":"ROIV","company_name":"Roivant Sciences Ltd.","filed_at":"2023-02-01T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the third quarter ended December 31, 2022","report_date":"2023-02-01","result_type":"preliminary_results","revenue_text":"between $9.0 million and $9.5 million"},"claim":"Roivant Sciences Ltd. reported the third quarter ended December 31, 2022 results: revenue between $9.0 million and $9.5 million.","evidence_excerpt":"In addition, for the third quarter ended December 31, 2022, the Company expects to report between $9.0 million and $9.5 million in net product revenues from VTAMA. This information is preliminary and unaudited and reflects the Company’s estimated financial results.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-23-003906","anchor_url":"https://secwatch.observer/filing/0001140361-23-003906#claim-d852e0522b9319861d45980546afcb86d8d96b0e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036123003906/0001140361-23-003906-index.htm"},{"fact_type":"executive_change","fact_key":"1c4bbc52c8","cik":1635088,"ticker":"ROIV","company_name":"Roivant Sciences Ltd.","filed_at":"2022-11-23T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2022-11-17","interim":false,"role":"Class II director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Andrew Lo resigned as Class II director at Roivant Sciences Ltd..","evidence_excerpt":"On November 17, 2022, Dr. Andrew Lo, a Class II director of Roivant Sciences Ltd. (the “Company”), informed the Company of his decision to resign from his role on the Company’s board of directors (the “Board”) effective immediately, to focus on other ventures.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-22-043040","anchor_url":"https://secwatch.observer/filing/0001140361-22-043040#claim-1c4bbc52c8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036122043040/0001140361-22-043040-index.htm"},{"fact_type":"earnings_release","fact_key":"6e0654dc7e22d96f763ea619cd8094bf9fa24955","cik":1635088,"ticker":"ROIV","company_name":"Roivant Sciences Ltd.","filed_at":"2022-11-14T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"fiscal quarter ended September 30, 2022","report_date":"2022-11-14","result_type":"reported_results","revenue_text":"$5.0 million"},"claim":"Roivant Sciences Ltd. reported fiscal quarter ended September 30, 2022 results: revenue $5.0 million.","evidence_excerpt":"Roivant reported VTAMA net product revenue of $5.0 million, representing a gross-to-net yield of approximately 12%.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-22-041169","anchor_url":"https://secwatch.observer/filing/0001140361-22-041169#claim-6e0654dc7e22d96f763ea619cd8094bf9fa24955","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036122041169/0001140361-22-041169-index.htm"},{"fact_type":"material_agreement","fact_key":"71f8321d19f3b4ec2df6ab1a87fdecc699474b82","cik":1635088,"ticker":"ROIV","company_name":"Roivant Sciences Ltd.","filed_at":"2022-11-10T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Underwriting Agreement","agreement_type":"underwriting","counterparty":"Cantor Fitzgerald & Co.","effective_date":"2022-11-08","item_codes_triggered":["1.01"],"value_text":"$150 million"},"claim":"Roivant Sciences Ltd. entered into Underwriting Agreement with Cantor Fitzgerald & Co. valued at $150 million (effective 2022-11-08).","evidence_excerpt":"On November 8, 2022, Roivant Sciences Ltd. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co. (the “Underwriter”), as the sole underwriter, and the selling shareholders named therein (the “Selling Shareholders”) relating to the issuance and sale in an underwritten offering (the “Offering”) of 30,000,000 (the “Shares”) of the Company’s common shares, par value $0.0000000341740141 per share, at an offering price of $5.00 per share.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001140361-22-040919","anchor_url":"https://secwatch.observer/filing/0001140361-22-040919#claim-71f8321d19f3b4ec2df6ab1a87fdecc699474b82","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036122040919/0001140361-22-040919-index.htm"},{"fact_type":"executive_change","fact_key":"524e06abaa","cik":1635088,"ticker":"ROIV","company_name":"Roivant Sciences Ltd.","filed_at":"2022-09-21T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-09-16","interim":false,"role":"Class III director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Hiroshi Nomura was appointed as Class III director at Roivant Sciences Ltd..","evidence_excerpt":"Also on September 15, 2022, the Board appointed Hiroshi Nomura to serve as a Class III director of the Board, effective September 16, 2022, filling the vacancy created by and concurrent with the resignation of Mr. Tada from the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-22-034294","anchor_url":"https://secwatch.observer/filing/0001140361-22-034294#claim-524e06abaa","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036122034294/0001140361-22-034294-index.htm"},{"fact_type":"executive_change","fact_key":"aaf608c081","cik":1635088,"ticker":"ROIV","company_name":"Roivant Sciences Ltd.","filed_at":"2022-09-21T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2022-09-16","interim":false,"role":"director","role_category":"director","successor_name":"Hiroshi Nomura","successor_named":true},"claim":"Masayo Tada resigned as director at Roivant Sciences Ltd..","evidence_excerpt":"On September 15, 2022, Masayo Tada resigned as a director of the Company, effective September 16, 2022.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001140361-22-034294","anchor_url":"https://secwatch.observer/filing/0001140361-22-034294#claim-aaf608c081","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036122034294/0001140361-22-034294-index.htm"},{"fact_type":"executive_change","fact_key":"62d8ce9061","cik":1635088,"ticker":"ROIV","company_name":"Roivant Sciences Ltd.","filed_at":"2022-06-28T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-06-29","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Melissa Epperly was appointed as Director at Roivant Sciences Ltd..","evidence_excerpt":"On June 22, 2022, the Board of Directors (the “Board”) of the Company appointed Melissa Epperly to serve as a Class I director of the Board and as a member of the Audit Committee of the Board, effective June 29, 2022, filling the vacancy created by, and concurrent with, the previously announced resignation of Patrick Machado from the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-22-183258","anchor_url":"https://secwatch.observer/filing/0001193125-22-183258#claim-62d8ce9061","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1635088/000119312522183258/0001193125-22-183258-index.htm"},{"fact_type":"executive_change","fact_key":"5476be6ad0","cik":1635088,"ticker":"ROIV","company_name":"Roivant Sciences Ltd.","filed_at":"2022-06-28T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2022-06-29","interim":false,"role":"Director","role_category":"director","successor_name":"Melissa Epperly","successor_named":true},"claim":"Patrick Machado resigned as Director at Roivant Sciences Ltd..","evidence_excerpt":"the previously announced resignation of Patrick Machado from the Board","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-22-183258","anchor_url":"https://secwatch.observer/filing/0001193125-22-183258#claim-5476be6ad0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1635088/000119312522183258/0001193125-22-183258-index.htm"},{"fact_type":"executive_change","fact_key":"3c11982572","cik":1635088,"ticker":"ROIV","company_name":"Roivant Sciences Ltd.","filed_at":"2021-10-01T23:59:59+00:00","payload":{"action":"stepped down","action_category":"role_change","departure_tone":"routine","effective_date":"2021-09-28","interim":false,"role":"Principal Financial Officer and Chief Financial Officer","role_category":"cfo","successor_name":"Richard Pulik","successor_named":true},"claim":"Matthew Gline changed role as Principal Financial Officer and Chief Financial Officer at Roivant Sciences Ltd..","evidence_excerpt":"Matthew Gline, who has been serving as Principal Financial Officer of the Company and Chief Financial Officer of RSI, will step down from those positions as of the Effective Date.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-21-288885","anchor_url":"https://secwatch.observer/filing/0001193125-21-288885#claim-3c11982572","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1635088/000119312521288885/0001193125-21-288885-index.htm"},{"fact_type":"executive_change","fact_key":"703d4ddbc2","cik":1635088,"ticker":"ROIV","company_name":"Roivant Sciences Ltd.","filed_at":"2021-10-01T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2021-09-28","interim":false,"role":"Principal Financial Officer and Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Richard Pulik was appointed as Principal Financial Officer and Chief Financial Officer at Roivant Sciences Ltd..","evidence_excerpt":"On September 28, 2021 (the “Effective Date”), the Company appointed Richard Pulik as Principal Financial Officer of the Company and as Chief Financial Officer of the Company’s subsidiary, Roivant Sciences, Inc. (“RSI”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-21-288885","anchor_url":"https://secwatch.observer/filing/0001193125-21-288885#claim-703d4ddbc2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1635088/000119312521288885/0001193125-21-288885-index.htm"}]}